Abevmy 400 mg/16 mL Injection
Abevmy 400 mg/16 mL Injection Abevmy 400 mg/16 mL is a bevacizumab injection used as a targeted cancer therapy. Bevacizumab is a recombinant humanized monoclonal antibody that blocks vascular endothelial growth factor (VEGF), a protein involved in the formation of new blood vessels.
By inhibiting VEGF, bevacizumab can reduce the formation of blood vessels that supply tumors, thereby helping to slow tumor growth and progression. Abevmy is a biosimilar bevacizumab product.
| Brand | Abevmy |
| Storage Temperature | 2°C–8°C |
| Prescription Needed | Yes |
| Composition | Bevacizumab |
| Strength | 400 mg/16 mL |
| Form | Sterile concentrate for solution for infusion |
| Pack Size | 1 × 16 mL single-use vial |
| Packaging | Vial |
| Country of Origin | Made In India |
| Manufacturer | Mylan Pharmaceuticals Pvt. Ltd. |
Abevmy 400 mg/16 mL Injection
Abevmy 400 mg/16 mL Injection Abevmy 400 mg/16 mL is a bevacizumab injection used as a targeted cancer therapy. Bevacizumab is a recombinant humanized monoclonal antibody that blocks vascular endothelial growth factor (VEGF), a protein involved in the formation of new blood vessels.
By inhibiting VEGF, bevacizumab can reduce the formation of blood vessels that supply tumors, thereby helping to slow tumor growth and progression. Abevmy is a biosimilar bevacizumab product.
